Beranda › Limfoma Burkitt › Kentucky
Uji klinis Limfoma Burkitt di Kentucky
5 studi untuk Limfoma Burkitt mencari peserta di lokasi di Kentucky.
Kota di Kentucky
Teks studi resmi (Bahasa Inggris)
A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)
- University of Kentucky/Markey Cancer Center, Lexington
- Norton Children's Hospital, Louisville
Menerima pesertaFase 2
366 Days – 46 Years · Semua jenis kelamin · Diperbarui 2 Okt 2026 · NCT06124157Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia
- University of Kentucky/Markey Cancer Center, Lexington
Menerima pesertaFase 3
Usia 18 hingga 39 · Semua jenis kelamin · Diperbarui 2 Okt 2026 · NCT03150693Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
- University of Kentucky/Markey Cancer Center, Lexington
- Norton Children's Hospital, Louisville
Menerima pesertaFase 2
365 Days · Semua jenis kelamin · Diperbarui 25 Sep 2026 · NCT06317662A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)
- University of Kentucky/Markey Cancer Center, Lexington
- Norton Children's Hospital, Louisville
Menerima pesertaFase 2
Usia 1 hingga 30 · Semua jenis kelamin · Diperbarui 1 Sep 2026 · NCT04546399Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
- University of Kentucky/Markey Cancer Center, Lexington
- Norton Children's Hospital, Louisville
Menerima pesertaFase 3
365 Days – 25 Years · Semua jenis kelamin · Diperbarui 25 Agu 2026 · NCT03959085Dari ClinicalTrials.gov, data diambil 5 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.